12 July 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2018.

Read more…

To access the link to the webcast please click here.

11 July 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusivity agreement with a US-based specialty pharmaceutical company in connection with the potential out-licensing of ReNeuron’s hRPC retinal stem cell technology and therapeutic programmes.

Read more…

04 May 2018:ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is today, as previously announced, hosting a capital markets event focused on the Company’s exosome nanomedicine platform.

Read more…

04 May 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new and positive pre-clinical data relating to its ExoPr0 stem cell-derived exosome therapy candidate will be presented today at ISCT 2018, a leading scientific conference taking place this week in Montreal, Canada.

Read more…

30 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be hosting a capital markets event on the Company’s exosome nanomedicine platform on Thursday 17 May 2018. The event, for analysts and institutional investors, will take place at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

Read more…

19 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new £1.5 million grant award from the UK’s innovation agency, Innovate UK, to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.

Read more…

10 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer.  He replaces Dr Julian Howell who has left the Company to pursue another opportunity.

Read more…

 

26 March 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update across its research and development programmes.

Read more…

Positive pre-clinical data published using ReNeuron’s CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration

26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the publication of new positive data in a pre-clinical model of nerve injury which demonstrated comparable nerve regeneration compared to standard of care treatment and a stronger muscle function response.

Read more …

Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018

26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that positive long-term data from the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability was accepted for a podium presentation given yesterday at the American Heart Association International Stroke Conference 2018 (“ISC 2018”),  taking place this week in Los Angeles.

Read more…

To view the presentation please click here.